SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001342
Filing Date
2024-08-13
Accepted
2024-08-13 08:16:03
Documents
75
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20240630x10q.htm   iXBRL 10-Q 1529988
2 EX-31.1 tmb-20240630xex31d1.htm EX-31.1 14807
3 EX-32.1 tmb-20240630xex32d1.htm EX-32.1 6837
4 GRAPHIC tmb-20240630x10q001.jpg GRAPHIC 53086
  Complete submission text file 0001410578-24-001342.txt   6892966

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20240630.xsd EX-101.SCH 50686
6 EX-101.CAL tmb-20240630_cal.xml EX-101.CAL 55332
7 EX-101.DEF tmb-20240630_def.xml EX-101.DEF 216260
8 EX-101.LAB tmb-20240630_lab.xml EX-101.LAB 420666
9 EX-101.PRE tmb-20240630_pre.xml EX-101.PRE 329435
78 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240630x10q_htm.xml XML 1079316
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 241198881
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)